Inclusion Criteria:

- Confirmed diagnosis of:

- Advanced solid tumor that is no longer responding to therapies OR

- Advanced or metastatic NSCLC that has previously been treated with erlotinib or
gefitinib

- ECOG Performance Status 0-1

- Adequate organ and bone arrow function as defined by hematological and serum
chemistry limits

- At least 18 years old

- Both men and women must practice adequate contraception

- Informed consent

Exclusion Criteria:

- Restriction of some therapies/medications within specific timeframes prior to
enrollment and during the study including prior therapy with PI3K, cytotoxic
chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase
inhibitors, non-cytotoxic hormonal agents

- Erlotinib intolerant

- Taking oral corticosteroids chronically or > 1 mg/day warfarin

- Not recovered from the toxic effects of prior therapy

- History of diabetes mellitus and an HgbA1c > 7%

- Uncontrolled intercurrent illness

- Pregnant or breastfeeding

- Congestive heart failure, unstable angina, or a myocardial infarction within 3 months
of entering the study.

- HIV positive

- Diagnosis of another malignancy may exclude subject from study